Glenmark Pharma

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - ESG Ratings

20 Feb, 2026 | 05:29pm • Source: BSE

Newspaper advertisement regarding Notice of Special Window for Transfer and Dematerialisation of physical shares

18 Feb, 2026 | 04:26pm • Source: BSE

The transcript of the Earnings Call held on Monday, February 02, 2026 has been uploaded on the Company''s website.

04 Feb, 2026 | 03:16pm • Source: BSE

Pursuant to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform the details of Analyst /...

02 Feb, 2026 | 04:39pm • Source: BSE

Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we...

02 Feb, 2026 | 01:38pm • Source: BSE

Disclosure under Regulation 30 of the SEBI (LODR) Regulation, 2015 - Regulatory Action/ Inspection

31 Jan, 2026 | 09:16pm • Source: BSE

Enclosed please find herewith the details of Earnings Call slated for Monday, February 02, 2026 at 8:30 a.m. - 9:30 a.m. (IST), for your information...

22 Jan, 2026 | 04:44pm • Source: BSE

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") - ESG Rating.

05 Jan, 2026 | 04:43pm • Source: BSE

Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/ 30 mL (1 mg/mL) Multiple - Dose Vial

23 Dec, 2025 | 08:44am • Source: BSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for...

11 Dec, 2025 | 11:15am • Source: NSE

Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/ vial Single - Dose Vial

11 Dec, 2025 | 08:44am • Source: BSE

Update on the Company''s Chhatrapati Sambhajinagar (Aurangabad) Facility

01 Dec, 2025 | 08:56am • Source: BSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 27, 2025, titled "Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S....

27 Nov, 2025 | 10:19am • Source: NSE

Update on the Company''s Monroe, North Carolina (USA) Facility

27 Nov, 2025 | 10:15am • Source: BSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Glenmark Pharmaceuticals Announces Launch of Nebzmart® GFB Smartules® and...

25 Nov, 2025 | 09:21am • Source: NSE

Glenmark Pharmaceuticals Announces Launch of Nebzmart GFB Smartules and Glenmark Airz FB Smartules, World''s First Nebulized Triple Therapy for COPD

25 Nov, 2025 | 09:00am • Source: BSE

Transcript of Earnings Call is attached

19 Nov, 2025 | 05:17pm • Source: BSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 18, 2025, titled "Cosmo and Glenmark Announce Market Authorization of Winlevi® (clascoterone)...

18 Nov, 2025 | 03:02pm • Source: NSE

Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we...

17 Nov, 2025 | 01:01pm • Source: BSE

Please find attached details of Analyst / Institutional Investor meeting.

14 Nov, 2025 | 06:19pm • Source: BSE